Week in Review: Week's China Life Science Deals Total Over $2.5 Billion

Deals and Financings   Zai Lab, a Shanghai biopharma, announced a four-drug CD3/CD47 bispecific Asia /global immunonocology deal with MacroGenics worth over $1.4 billion; Shanghai's HutchMed is planning to raise $600 million in a Hong Kong IPO to support its portfolio of ten oncology drugs including two launched candidates; Beijing 's LinkDoc Technology, an AI driven healthcare company based on cancer patient data, filed for a NASDAQ IPO worth up to $500 million; HiFiBiO, a US-China biotech, closed a $75 million Series D financing to support clinical trials of its two leading antibody therapies for oncology; Shanghai 's HuiGene Therapeutics completed a $62 million Series B round for its gene editing tools and gene-edited rare disease drugs; OncoNano Medicine of Texas raised $50 million for its novel pH-based cancer products in a B round led by Advantech, a  China  cross border investor;  Trials and Approvals   Suzhou Innovent Bio dosed the first person in a China Phase II trial of a dual agonist treatment for obesity that it in-licensed from Lilly; ImmVira of Shenzhen started a China/US Phase II trial of its lead drug, an oncolytic virus product for solid tumors and melanoma;   Sirnaomics, a Maryland-Suzhou RNAi company, will add a China Phase IIb trial for its lead drug in patients with skin squamous cell carcinoma; Beijing Jacobio Pharma dosed the first two patients in a Phase I/IIa trial of its SHP2 inhibitor in patients with solid tumor cancer; Asieris Pharma of  Shanghai  has been approved to start US trials of its MetAP2 inhibitor in patients with muscle invasive bladder cancer.  Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: MGNX) (NSDQ/AIM: HCM) (HK: 01801) (HK: 1167) Share this with colleagues: // //